Hemerion will present its therapy at the Congress of Neurosurgeons’ Annual Meeting.

Hemerion continues its international expansion with its first participation in the world’s largest neurosurgery event. This is an opportunity to preview its upcoming pivotal multicenter clinical trial to the most influential specialists in global neurosurgery.

The Annual Meeting of the Congress of Neurosurgeons will be held at the Los Angeles Convention Center from October 10 to 15, 2025.  Entitled “CNS Connects,” the congress is the world’s largest neurosurgery event.

Present the Pentalafen®/Heliance® combination therapy to key opinion leaders in the neurosurgery sector

Hemerion will present its Pentalafen®/Heliance® combination therapy for treating glioblastoma.
There will be demonstrations of the technology in real-world conditions, as well as discussion sessions on the clinical results recorded by the technology during the three clinical trials conducted.

Hemerion will also participate in a symposium dedicated to neuro-oncology, the Joint Tumor Section.

Prepare for the launch of the pivotal clinical phase, the final clinical stage before market access operations

This participation also aims to establish an initial network of investigators in preparation for the multicenter pivotal study that will follow the Phase 1/2 clinical trials currently underway at the University of Pittsburgh Medical Center in the US and Lille University Hospital in Europe.
Hemerion also aims to respond to the interest expressed by many neurosurgeons in the possibilities offered by its technology for treating glioblastoma and other types of brain cancer.